Publicaciones en las que colabora con Nadine Jagerovic (17)

2023

  1. Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure-Activity Relationship

    ACS Medicinal Chemistry Letters, Vol. 14, Núm. 1, pp. 18-25

2021

  1. Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis

    Molecules, Vol. 26, Núm. 24

2020

  1. Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB2 Receptor**

    Chemistry - A European Journal, Vol. 26, Núm. 68, pp. 15839-15842

2017

  1. Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)

    Pharmacological Research

  2. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking

    European Journal of Medicinal Chemistry, Vol. 127, pp. 398-412

  3. Synthesis of a novel CB2 cannabinoid-porphyrin conjugate based on an antitumor chromenopyrazoledione

    Journal of Porphyrins and Phthalocyanines, Vol. 21, Núm. 1, pp. 67-76

2016

  1. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile

    Pharmacological Research, Vol. 110, pp. 205-215

  2. Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis

    Journal of Medicinal Chemistry, Vol. 59, Núm. 14, pp. 6753-6771

  3. Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology

    Journal of Medicinal Chemistry, Vol. 59, Núm. 5, pp. 1840-1853

  4. Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders

    Frontiers in Neuroscience, Vol. 10, Núm. SEP

2015

  1. Selective, nontoxic CB2 cannabinoid o-quinone with in vivo activity against triple-negative breast cancer

    Journal of Medicinal Chemistry, Vol. 58, Núm. 5, pp. 2256-2264

  2. Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists

    European Journal of Medicinal Chemistry, Vol. 101, pp. 651-667

2014

  1. Combining rimonabant and fentanyl in a single entity: Preparation and pharmacological results

    Drug Design, Development and Therapy, Vol. 8, pp. 263-277

2013

  1. Description of a bivalent cannabinoid ligand with hypophagic properties

    Archiv der Pharmazie, Vol. 346, Núm. 3, pp. 171-179

  2. Novel antiobesity agents: Synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21

    Bioorganic and Medicinal Chemistry, Vol. 21, Núm. 7, pp. 1708-1716

  3. Synthetic cannabinoid quinones: Preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity

    European Journal of Medicinal Chemistry, Vol. 70, pp. 111-119

2012

  1. Chromenopyrazoles: Non-psychoactive and Selective CB 1 Cannabinoid Agonists with Peripheral Antinociceptive Properties

    ChemMedChem, Vol. 7, Núm. 3, pp. 452-463